Additional file 2 of miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

Additional file 1: Supplementary Table S1. List of used antibodies and molecular probes. Supplementary Table S2. Differentially expressed miR between cell lines with acquired resistance to vemurafenib and their sensitive counterparts. Supplementary Table S3. Genes directly targeted by miR-146a among the NFkB-regulated genes differentially expressed in LM16R/LM16 dataset (GSE68841). Supplementary Table S4. Characteristics of patients treated with vemurafenib and their matched pre- and post-treatment melanoma metastasis (GSE141484).

附加文件1：补充表S1。所用抗体与分子探针列表。
补充表S2。维莫非尼获得性耐药细胞系与其敏感对应细胞系间的差异表达微小RNA（miR，microRNA）。
补充表S3。LM16R/LM16数据集（GSE68841）中，受核因子κB（NFκB）调控且差异表达的基因集合内，miR-146a直接靶向的基因列表。
补充表S4。接受维莫非尼治疗的患者及其配对的治疗前、治疗后黑色素瘤转移灶样本的临床特征（数据集GSE141484）。